Item 1.01 Entry into a Material Definitive Agreement · On September 21, 2016, Hyperdynamics Corporation (“Hyperdynamics,” the “Company,” “we” or “us”), through its wholly-owned subsidiary, SCS Corporation (“SCS”) received an implementing Presidential Decree from the Republic of Guinea authorizing a Second Amendment (the “Second Amendment”) to the Hydrocarbon Production Sharing Contract, dated September 22, 2006, between SCS and the Republic of Guinea, as amended on Marc...
Exhibit Number, Exhibit Title or Description ; 23.1, Consent of Ernst & Young LLP, Avast plc’s independent auditors. ; 99.1, Management’s Discussion and Analysis of Financial Condition and Results of Operations of Avast. ; 99.2, Investor presentation, dated September 7, 2022. ; 99.3, Risks Related to the Avast plc Business. ; 99.4, Unaudited pro forma condensed combined financial information of NortonLifeLock Inc. giving effect to the acquisition of Avast plc, which includes the unaudited pro forma condensed combined statement of financial position as of July 1, 2022 and the unaudited pro forma condensed combined statement of comprehensive income for the year ended April 1, 2022 and the three months ended July 1, 2022, and the notes related thereto. ; 99.5, The historical audited consolidated financial statements and financial statement schedule of Avast plc as of and for each of the years ended December 31, 2021 and 2020, the notes related thereto and the related reports of Ernst & Young LLP, Avast plc’s independent auditors. ; 99.6, The historical unaudited condensed consolidated financial statements and financial statement schedule of Avast plc as of and for each of the six months ended June 30, 2022 and 2021, and the notes related thereto. ; 104, The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.
Item 7.01 Regulation FD Disclosure. Exhibit 99.1 contains IBM’s presentation materials for the morning session of IBM’s Investor Briefing on March 7, 2017. The information in this Item 7.01, including the corresponding Exhibit 99.1, is being furnished with the Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”). These materials may contain forward-looking statements under the Private Securities Litigation R...
Item 7.01 Regulation FD Disclosure. On January 3, 2019, BioXcel Therapeutics, Inc. (the “Company”) held an investor conference call and discussed the results of the study described in Item 8.01 below and the Company’s BXCL501 program. In connection with the investor call, the Company prepared presentation materials (“the Presentation Materials”), a copy of which are furnished as Exhibit 99.1 to this current report on Form 8-K. The call will be available via a live, listen-only webcast ...
Disclaimer ; Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s expectations; beliefs; plans; strategies; investments; financial performance; expected benefits of new initiatives; content, products, experiences or service offerings (including timing and nature); priorities or performance; businesses and assets; future investments and crea...
EX-10.1 2 tm2217179d1_ex10-1.htm EXHIBIT 10.1 ; Exhibit 10.1 · Execution Version · SIXTH AMENDED AND RESTATED CREDIT AGREEMENT · dated as of May 27, 2022 · among · UNITED STATES STEEL CORPORATION · THE LENDERS PARTY HERETO · THE LC ISSUING BANKS PARTY HERETO and · JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent · JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A., WELLS FARGO BANK, NATIONAL ASSOCIATION, and · BARCLAYS BANK PLC, as Joint Lead Arrangers an...
Item 2.02. Results of Operations and Financial Condition. The registrant’s press release dated January 22, 2019, regarding its financial results for the periods ended December 31, 2018, including consolidated financial statements for the periods ended December 31, 2018, is Exhibit 99.1 of this Form 8-K. In an effort to provide investors with additional information regarding the company’s results as determined by generally accepted accounting principles (GAAP), the company has disclosed in th...
UNITED STATES · SECURITIES AND EXCHANGE COMMISSION · WASHINGTON, D.C. 20549 · FORM 8-K · CURRENT REPORT · PURSUANT TO SECTION 13 OR 15(D) OF THE · SECURITIES EXCHANGE ACT OF 1934 · Date of Report (date of earliest event reported): June 9, 2021 · (Exact name of registrant as specified in its charter)
Item 2.02. Results of Operations and Financial Condition. The registrant’s press release dated January 19, 2012, regarding its financial results for the periods ended December 31, 2011, including consolidated financial statements for the periods ended December 31, 2011, is Attachment I of this Form 8-K. Attachment II are the slides for IBM’s Chief Financial Officer Mark Loughridge’s fourth quarter earnings presentation on January 19, 2012, as well as certain reconciliation and other inform...
Item 7.01 (Regulation FD Disclosure) ; Attachment I contains presentation materials for the afternoon session of IBM’s Investor Briefing on May 14, 2014. See Attachment II (non-GAAP supplemental materials) in the Form 8-K dated May 14, 2014 filed earlier today, which contains supplemental materials about non-GAAP financial measures in certain presentation materials for the morning and afternoon sessions of this event. IBM’s web site (www.ibm.com) contains a significant amount of information ...